| Mohammad Asim Malik, DO | |
|
1100 Central Ave Se, Presbyterian Hospital, Albuquerque, NM 87106-4930 | |
| (505) 724-6124 | |
| Not Available |
| Full Name | Mohammad Asim Malik |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 16 Years |
| Location | 1100 Central Ave Se, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538396163 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | RS12345 (New Mexico) | Secondary |
| 207R00000X | Internal Medicine | A-1829-14 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lovelace Medical Center | Albuquerque, NM | Hospital |
| Lovelace Women's Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cura Healthcare | 5799143103 | 21 |
| Southwest Medical Associates, Llc | 7214831114 | 291 |
News Archive
BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.
In almost ten per cent of myocardial infarctions, no obvious cause in the coronary artery can be found. Some of the patients are diagnosed with broken-heart syndrome, while others are left without a diagnosis.
By artificially activating the brain's reward system, researchers at the Technion-Israel Institute of Technology have dramatically reduced the size of cancerous tumors in mice. The findings were published recently in the journal Nature Communications.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
› Verified 3 days ago
| Entity Name | Southwest Medical Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164491072 PECOS PAC ID: 7214831114 Enrollment ID: O20031121000724 |
News Archive
BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.
In almost ten per cent of myocardial infarctions, no obvious cause in the coronary artery can be found. Some of the patients are diagnosed with broken-heart syndrome, while others are left without a diagnosis.
By artificially activating the brain's reward system, researchers at the Technion-Israel Institute of Technology have dramatically reduced the size of cancerous tumors in mice. The findings were published recently in the journal Nature Communications.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
› Verified 3 days ago
| Entity Name | Daiya Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477027381 PECOS PAC ID: 6002158615 Enrollment ID: O20200903001256 |
News Archive
BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.
In almost ten per cent of myocardial infarctions, no obvious cause in the coronary artery can be found. Some of the patients are diagnosed with broken-heart syndrome, while others are left without a diagnosis.
By artificially activating the brain's reward system, researchers at the Technion-Israel Institute of Technology have dramatically reduced the size of cancerous tumors in mice. The findings were published recently in the journal Nature Communications.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
› Verified 3 days ago
| Entity Name | Cura Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649984667 PECOS PAC ID: 5799143103 Enrollment ID: O20230616001109 |
News Archive
BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.
In almost ten per cent of myocardial infarctions, no obvious cause in the coronary artery can be found. Some of the patients are diagnosed with broken-heart syndrome, while others are left without a diagnosis.
By artificially activating the brain's reward system, researchers at the Technion-Israel Institute of Technology have dramatically reduced the size of cancerous tumors in mice. The findings were published recently in the journal Nature Communications.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mohammad Asim Malik, DO 1100 Central Ave Se, Presbyterian Hospital, Albuquerque, NM 87106-4930 Ph: (505) 724-6124 | Mohammad Asim Malik, DO 1100 Central Ave Se, Presbyterian Hospital, Albuquerque, NM 87106-4930 Ph: (505) 724-6124 |
News Archive
BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.
In almost ten per cent of myocardial infarctions, no obvious cause in the coronary artery can be found. Some of the patients are diagnosed with broken-heart syndrome, while others are left without a diagnosis.
By artificially activating the brain's reward system, researchers at the Technion-Israel Institute of Technology have dramatically reduced the size of cancerous tumors in mice. The findings were published recently in the journal Nature Communications.
Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today a significant progress on the discussions to implement the company's safety pre-matching locking device technology for blood transfusion vials with Israel's national Emergency Medical Services Provider who oversee the entire Nation's Blood Banks.
In what may be a major leap forward in the quest for new treatments of the most common form of cardiovascular disease, scientists at Johns Hopkins report they have found a way to halt and reverse the progression of atherosclerosis in rodents by loading microscopic nanoparticles with a chemical that restores the animals' ability to properly handle cholesterol.
› Verified 3 days ago
Dr. Alberto Aguayo Rico, M.D, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 San Mateo Blvd Se, Albuquerque, NM 87108 Phone: 505-462-7333 Fax: 505-462-7440 | |
Peter Guido, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 4700 Jefferson St Ne, Ste 800, Albuquerque, NM 87109 Phone: 505-872-6000 Fax: 505-872-6003 | |
Kenneth A Bell, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2901 Transport St Se, Albuquerque, NM 87106 Phone: 505-262-7110 Fax: 505-262-7308 | |
Joseph F. Oser, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1501 San Pedro Dr Se, Albuquerque, NM 87108 Phone: 505-265-1711 | |
Dr. Stanley Zissman Berman, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 7416 Vista Del Arroyo Ave Ne, Albuquerque, NM 87109 Phone: 505-884-7270 | |
Huyentrang Vu, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: Unm Hospital Internal Medicine, 2211 Lomas Blvd Ne, Albuquerque, NM 87131 Phone: 505-272-6225 | |
Tamara Goodman, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 4901 Lang Ave Ne, Albuquerque, NM 87109 Phone: 505-842-8171 |